Year 2024 / Volume 116 / Number 4
Editorial
Hemophilia and hepatology, back to the future

179-181

DOI: 10.17235/reed.2024.10105/2023

Antonio Olveira, Víctor Jiménez,

Abstract
Years ago, patients with hemophilia were often cared for because of liver issues. The use of hemoderivatives in the 1970s and 1980s, and the natural history of chronic hepatitis B and C, led to a surge of patients with cirrhosis and related complications after two or three decades. It was not until the approval of entecavir and tenofovir (2005-2008) against the B virus, and of direct-acting antiviral agents (2015) against the C virus, that a truly effective treatment became available for liver disease. Since then, patients with hemophilia disappeared from hepatology clinics and wards, apart from specific isolated problems.
Share Button
New comment
Comments
No comments for this article
References
1. Qvigstad C, Tait RC, Rauchensteiner S, et al. The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment. Medicine (Baltimore) 2018;97:e12551.
2. https://www.ema.europa.eu/en/medicines/human/EPAR/roctavian-0 [Internet] 2022. Consultado 11 de noviembre de 2023.
3. https://www.ema.europa.eu/en/medicines/human/EPAR/hemgenix [Internet] 2023. Consultado 11 de noviembre de 2023.
4. D’Antiga L, Beuers U, Ronzitti G, et al. Gene therapy in patients with the Crigler-Najjar syndrome. N Engl J Med 2023;389:620-31.
5. Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther 2021;29:464-88.
6. Perocheau DP, Cunningham S, Lee J, et al. Age-related seroprevalence of antibodies against AAV-LK03 in a UK population cohort. Hum Gene Ther 2019;30:79-87.
7. Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med 2022;386:1013-25.
8. Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med 2023;388:706-18.
9. Shah J, Kim H, Sivamurthy K, Monahan PE, Fries M. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B. Current Medical Research and Opinion 2023;39:227-37.
10. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 2019;70:1222-61.
11. Verdera HC, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther 2020;28:723-46.
12. Fong S, Handyside B, Sihn CR, et al. Induction of ER stress by an AAV5 BDD FVIII construct is dependent on the strength of the hepatic-specific promoter. Mol Ther Methods Clin Dev 2020;18:620-30.
13. Gil-Farina I, Fronza R, Kaeppel C, et al. Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol Ther 2016;24:1100-05.
14. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990;87:2211-5.
15. Schmidt M, Foster GR, Coppens M, et al. Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B. Blood Adv 2023;7:4966-69.
16. Colombo M, Mannucci PM, Brettler DB, et al. Hepatocellular carcinoma in hemophilia. Am J Hematol 1991;37:243-6.
17. Duchini A, Viernes ME, Nyberg LM, Hendry RM, Pockros PJ. Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch Intern Med 2000;160:113-5.
18. Bajaj JS, Garcia-Tsao G, Biggins SW, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut 2021;70:531-36.
19. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89.
20. Kapelanski-Lamoureux A, Chen Z, Gao ZH, et al. Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma. Mol Ther 2022;30:3542-51.
Related articles

Letter

Turmeric associated liver injury (DILI) with susceptible HLA

DOI: 10.17235/reed.2024.10763/2024

Letter

Cefditoren-induced hepatitis

DOI: 10.17235/reed.2022.8801/2022

Letter

Curcumin and curcumoids: hepatoprotection or hepatotoxicity?

DOI: 10.17235/reed.2022.8588/2022

Digestive Diseases Image

Giant cystic hepatocarcinoma in the absence of cirrhosis

DOI: 10.17235/reed.2021.8313/2021

Letter

Severe hepatotoxicity secondary to nintedanib

DOI: 10.17235/reed.2020.7585/2020

Letter

Biopsy for hepatocellular carcinoma: only occasionally

DOI: 10.17235/reed.2020.6935/2020

Letter

Hepatocarcinoma diagnosis. Reflection is required

DOI: 10.17235/reed.2020.6845/2019

Letter

Rhabdomyolysis in a patient under treatment with sorafenib

DOI: 10.17235/reed.2020.6440/2019

Case Report

Ectopic hepatocellular carcinoma arising from the peritoneum

DOI: 10.17235/reed.2019.6408/2019

Case Report

Apixaban-induced liver injury

DOI: 10.17235/reed.2018.5877/2018

Letter to the Editor

Canalicular cholestasis induced by anabolic steroids

DOI: 10.17235/reed.2017.4781/2016

Digestive Diseases Image

Debut of an unusual liver cirrhosis

Review

New challenges in clinical research on hepatocellular carcinoma

DOI: 10.17235/reed.2015.4012/2015

Citation tools
Olveira A, Jiménez V. Hemophilia and hepatology, back to the future. 10105/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1310 visits.
This article has been downloaded 138 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 21/11/2023

Accepted: 27/11/2023

Online First: 07/03/2024

Published: 09/04/2024

Article Online First time: 107 days

Article editing time: 140 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology